Status:
NOT_YET_RECRUITING
Mitochondrial DNA Deletions in Plasma as a Diagnostic Aid for Females Presenting With Symptoms of Endometriosis
Lead Sponsor:
Pearsanta, Inc
Conditions:
Endometriosis
Eligibility:
FEMALE
Brief Summary
This study will investigate the clinical performance and diagnostic accuracy of the Mitomic® Endometriosis Test (MET) compared to laparoscopic diagnosis in a prospective clinical study in females pres...
Eligibility Criteria
Inclusion
- Be female, between menarche and menopause who present with symptoms of endometriosis at time of blood collection and are scheduled to undergo their first laparoscopic procedure for the diagnosis of endometriosis
- Provide a blood sample prior to surgical procedure or administration of drugs related to the surgical procedure (i.e. anaesthetics, antibiotics)
- Be fit to undergo all procedures listed in protocol
- Be able to provide written informed consent
Exclusion
- Has had a prior surgical diagnosis of endometriosis at time of blood collection
- Is unable to communicate in written and spoken English
- Has any other condition, which in the opinion of the investigator, would make the subject not a suitable candidate for the study. This reason must be recorded on the CRF
Key Trial Info
Start Date :
April 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2030
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06907550
Start Date
April 1 2025
End Date
April 1 2030
Last Update
April 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pearsanta, Inc.
Richmond, Virginia, United States, 23219